AtaiBeckley Inc.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing innovative psychedelic-based neuroplastogens and related therapeutics for mental health disorders. It specializes in rapid-acting, durable, and convenient treatments targeting conditions such as treatment-resistant depression, social anxiety disorder, and other psychiatric issues where traditional therapies often fall short. The company's pipeline features modalities like intranasal sprays, oral transmucosal films, oral tablets, 5-HT2A receptor agonists, and non-hallucinogenic psychedelics, with lead candidates advancing through Phase 2 and Phase 2b/3-ready stages. AtaiBeckley Inc. operates at the forefront of psychedelic science and neuropharmacology, conducting active clinical trials to address significant unmet needs in psychiatry. Its therapeutic areas emphasize patient-first, evidence-based approaches for large-scale impact. Formed in 2025 through the combination of atai Life Sciences and Beckley Psytech, and headquartered in Berlin, Germany following U.S. redomiciliation, AtaiBeckley Inc. plays a pivotal role in advancing transformative mental health solutions within the biotechnology sector.